Less than a week after Human Genome Sciences Inc. won FDA approval for the first new lupus therapy in almost 60 years – a multi-billion-dollar blockbuster – HGS has dipped into its coffers to the tune of a potential $495 million for FivePrime Therapeutics Inc.'s FP-1039 product for multiple cancers, a drug still in a small Phase I trial.